Track Wave Life Sciences Ltd. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Wave Life Sciences Ltd. WVE · Stock Open Wave Life Sciences Ltd. in new tab

3.13 USD
EPS
-1.07
P/B
1.68
ROE
-78.80
Beta
-1.44
Target Price
16.84 USD
Wave Life Sciences Ltd. logo

Wave Life Sciences Ltd.

🧾 Earnings Recap – Q3 2026

Wave shares rose 7.5% after earnings, as investors appeared to reward progress in its pipeline—particularly the initiation of a WVE-007 combination trial and a GSK-selected siRNA candidate. The quarter’s key near-term catalyst remains pending: 600-mg WVE-007 data are expected this quarter.

  • WVE-007’s Phase I single-dose study showed reductions in visceral and total fat, lean-mass preservation, favorable tolerability, and dose-dependent activin E suppression, according to management.
  • Wave expects Phase I data for the 600-mg dose this quarter to further characterize potency, duration, safety, and tolerability.
  • The company initiated a Phase II-A combination trial of WVE-007 with weekly tirzepatide in people with BMI of 35–50 and type 2 diabetes.
  • Wave is also evaluating WVE-007 as monotherapy in a higher-BMI population and as post-incretin maintenance therapy; management says the monotherapy study will assess cardiometabolic biomarkers, including liver fat.
  • GSK selected an siRNA development candidate to transition into its pipeline during the quarter.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-1.07
Book Value2.04
Price to Book1.68
Debt/Equity10.77
% Insiders15.579%
Growth
Revenue Growth0.73%
Estimates
Forward P/E-2.88
Forward EPS-1.19
Target Mean Price16.84

DCF valuation

Model fair value for Wave Life Sciences Ltd. (WVE)
Result
Sign in to run the valuation for WVE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
19 analysts · consensus Strong buy · mean target 16.84 USD (low 10.00, high 44.00) · as of 11 Nov 2026
Low 10.00
Mean 16.84
High 44.00
Price 3.13
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Wave Life Sciences Ltd. Logo Wave Life Sciences Ltd. Analysis (WVE)

Singapore Health Care Official Website Stock

Is Wave Life Sciences Ltd. a good investment? Wave Life Sciences Ltd. (WVE) is currently trading at 3.13 USD. Market analysts have a consensus price target of 16.84 USD. This suggests a potential upside from current levels.

Earnings Schedule: Wave Life Sciences Ltd. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -1.19.

Investor FAQ

Does Wave Life Sciences Ltd. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Wave Life Sciences Ltd.?

Wave Life Sciences Ltd. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -1.07.

Company Profile

Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
SG9999014716
NGM (Sweden) WVE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion